Evidence map›Paper›PMID 30393375›Full record

ArticleCancer gene therapy2019

Phase I trial of intravenous Ad5CRT in patients with liver metastasis of gastrointestinal cancers.

Sang-Jin Lee, Seung-Pil Shin, Seung Hee Lee, Jeong Won Kang, Myeong-Cherl Kook, In-Hoo Kim, Hark Kyun Kim

Abstract readClinical Trial, Phase I
PubMed Publisher
In one paragraph

Article in Cancer gene therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Repair of MutatedCancers · 2025
    Article
  3. Review
  4. Article
  5. RNA Therapeutics - Research and Clinical Advancements.Frontiers in molecular biosciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Sang-Jin LeeNational Cancer Center, Goyang, Gyeonggi, 10408, Republic of Korea.
Seung-Pil ShinNational Cancer Center, Goyang, Gyeonggi, 10408, Republic of Korea.
Seung Hee LeeNational Cancer Center, Goyang, Gyeonggi, 10408, Republic of Korea.
Jeong Won KangNational Cancer Center, Goyang, Gyeonggi, 10408, Republic of Korea.
Myeong-Cherl KookNational Cancer Center, Goyang, Gyeonggi, 10408, Republic of Korea.
In-Hoo KimNational Cancer Center, Goyang, Gyeonggi, 10408, Republic of Korea.
Hark Kyun KimNational Cancer Center, Goyang, Gyeonggi, 10408, Republic of Korea. hkim@ncc.re.kr.
National Cancer Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We conducted a phase 1 trial for single-dose intravenous Ad5CRT, a replication-defective adenovirus vector expressing HSVtk (herpes simplex virus thymidine kinase) modulated by a specific trans-splicing ribozyme that targets human telomerase reverse transcriptase (hTERT)-encoding RNAs. Dose-limiting toxicities (DLTs) were evaluated in 15 patients at dose levels of 0.1-2 × 10

Indexed as

AdenoviridaeAdministration, IntravenousAdultAgedAged, 80 and overFemaleGastrointestinal NeoplasmsGenetic TherapyGenetic VectorsHerpes SimplexHumansLiver NeoplasmsMaleMiddle AgedNeoplasm MetastasisTelomeraseTelomeraseTERT protein, humanThymidine Kinase

Identifiers

PMID30393375
OpenAlexW2899103461

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.